121 related articles for article (PubMed ID: 8666362)
21. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
[TBL] [Abstract][Full Text] [Related]
22. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis.
Craanen ME; Blok P; Offerhaus GJ; Meijer GA; Dekker W; Kuipers EJ; Meuwissen SG
J Pathol; 1999 Dec; 189(4):481-6. PubMed ID: 10629547
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas.
Harlozińska A; Bar J; Montenarh M
Anticancer Res; 2000; 20(2A):1049-56. PubMed ID: 10810396
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic and p53 profiles in congenital cystic adenomatoid malformation: insights into its relationship with pleuropulmonary blastoma.
Vargas SO; Korpershoek E; Kozakewich HP; de Krijger RR; Fletcher JA; Perez-Atayde AR
Pediatr Dev Pathol; 2006; 9(3):190-5. PubMed ID: 16944975
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
Uchida T; Gao JP; Wang C; Jiang SX; Muramoto M; Satoh T; Minei S; Shimura S; Irie A; Kameya T; Baba S
Urology; 2002 Apr; 59(4):615-20. PubMed ID: 11927338
[TBL] [Abstract][Full Text] [Related]
26. Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.
Hao XP; Günther T; Roessner A; Price AB; Talbot IC
Mol Pathol; 1998 Feb; 51(1):26-9. PubMed ID: 9624416
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas.
Würl P; Meye A; Berger D; Bache M; Lautenschläger C; Schmidt H; Kalthoff H; Rath FW; Taubert H
Diagn Mol Pathol; 1997 Oct; 6(5):249-54. PubMed ID: 9458382
[TBL] [Abstract][Full Text] [Related]
29. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
30. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Droller MJ
J Urol; 2001 May; 165(5):1811-2. PubMed ID: 11345951
[No Abstract] [Full Text] [Related]
31. Expression of p53 is significantly associated with recurrence-free survival and overall survival in pleuropulmonary blastoma (PPB): a report from the International Pleuropulmonary Blastoma/DICER1 Registry.
González IA; Mallinger P; Watson D; Harris AK; Messinger YH; Schultz KAP; Field A; Hill DA; Dehner LP
Mod Pathol; 2021 Jun; 34(6):1104-1115. PubMed ID: 33637876
[TBL] [Abstract][Full Text] [Related]
32. Proliferative activity, p53 accumulation and neoangiogenesis in pulmonary carcinosarcomas and pulmonary blastomas.
Theegarten D; Zorn M; Philippou S
Gen Diagn Pathol; 1998 Apr; 143(5-6):265-70. PubMed ID: 9653906
[TBL] [Abstract][Full Text] [Related]
33. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
34. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
35. p53, MDM2, bcl-2 staining in follicular neoplasms of the thyroid gland.
Czyz W; Kuzdak K; Pasieka Z; Timler D; Brzeziński J
Folia Histochem Cytobiol; 2001; 39 Suppl 2():167-8. PubMed ID: 11820589
[TBL] [Abstract][Full Text] [Related]
36. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.
Jacobs TW; Prioleau JE; Stillman IE; Schnitt SJ
J Natl Cancer Inst; 1996 Aug; 88(15):1054-9. PubMed ID: 8683636
[TBL] [Abstract][Full Text] [Related]
37. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
[TBL] [Abstract][Full Text] [Related]
38. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
[TBL] [Abstract][Full Text] [Related]
39. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
40. p53 and MDM2 expression in oral squamous cell carcinoma.
Matsumura T; Yoshihama Y; Kimura T; Shintani S; Alcalde RE
Oncology; 1996; 53(4):308-12. PubMed ID: 8692535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
